{"gene":"TGFB2","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2012,"finding":"Heterozygous loss-of-function mutations or deletions in TGFB2 cause aortic root aneurysm in Tgfb2+/- mice with biochemical evidence of increased canonical and noncanonical TGF-β signaling, indicating that TGFB2 haploinsufficiency paradoxically upregulates TGF-β signaling in aortic tissue.","method":"Genetic mouse model (Tgfb2+/- haploinsufficient mice), western blotting for signaling markers, compound mutant mice with Fbn1(C1039G/+)","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal genetic and biochemical evidence in both human patients and mouse models, replicated across two independent Nature Genetics papers in the same year","pmids":["22772368","22772371"],"is_preprint":false},{"year":2012,"finding":"TGFB2 haploinsufficiency (frameshift and nonsense mutations causing loss of function) predisposes to thoracic aortic aneurysm and dissection; paradoxically, aortic tissue from affected individuals shows increased TGF-β2 expression and immunostaining, suggesting an initial decrease in cellular TGF-β2 leads to a secondary compensatory increase.","method":"Genome-wide linkage analysis, whole-exome sequencing, Sanger sequencing, immunostaining of aortic tissue from affected individuals","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (linkage, sequencing, tissue immunostaining), replicated in independent cohort in companion paper","pmids":["22772371"],"is_preprint":false},{"year":2018,"finding":"ΔNp63α transcriptionally represses TGFB2 expression; upon ΔNp63α depletion, TGFB2 is upregulated, which activates RHOA and induces cell cycle arrest in squamous cell carcinomas. Ectopic TGFB2 activates RHOA and impairs SCC proliferation, and TGFB2 neutralization restores cell proliferation during ΔNp63α depletion.","method":"Genome-wide CRISPR screen, RHOA activity assays, transcriptome analysis, ΔNp63α knockdown, ectopic TGFB2 expression, TGFB2 neutralizing antibody","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including CRISPR screen, rescue experiments with ectopic TGFB2 and neutralization, epistasis established","pmids":["30232004"],"is_preprint":false},{"year":2019,"finding":"Constitutive activation of a TGFB2 enhancer, maintained through epigenetic memory (H3K27ac), drives autocrine TGFβ2 signaling and enforces a profibrotic synthetic state in SSc fibroblasts. NF-κB and BRD4 inhibition suppresses TGFB2 enhancer activity and reverses dermal fibrosis in patient skin explants.","method":"Chromatin accessibility profiling (ATAC-seq), transcriptome profiling, targeted epigenetic editing (CRISPRi), NF-κB and BRD4 inhibition, patient skin explants","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — targeted epigenetic editing plus functional phenotypic readout in patient explants, multiple orthogonal methods in single lab","pmids":["31217334"],"is_preprint":false},{"year":2016,"finding":"RUNX1 depletion in hESCs specifically compromises TGFB2 (but not TGFB1) signaling, impairing cell motility and epithelial-to-mesenchymal transition during mesendodermal differentiation. Reintroduction of TGFB2 (not TGFB1) rescues both decreased motility and deregulated epithelial marker expression caused by RUNX1 loss.","method":"RUNX1 depletion by siRNA, transcriptome profiling, cell motility assays, rescue experiments with exogenous TGFB2 and TGFB1","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific rescue experiment provides clear mechanistic placement, single lab with multiple orthogonal methods","pmids":["27720906"],"is_preprint":false},{"year":2021,"finding":"HOXA10 binds to the TGFB2 promoter (shown by ChIP-qPCR), promotes TGFB2 transcription and secretion, thereby triggering TGFβ/Smad signaling with nuclear Smad2/3 accumulation, which in turn upregulates METTL3 expression and promotes EMT in gastric cancer cells. CoIP demonstrated Smad proteins mediate METTL3 expression.","method":"ChIP-qPCR, dual-luciferase reporter assay, CoIP, western blot, colorimetric m6A assay, in vivo lung metastasis rescue models","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-qPCR and CoIP with functional rescue in vivo, single lab with multiple orthogonal methods","pmids":["33563300"],"is_preprint":false},{"year":2024,"finding":"METTL14-mediated N6-methyladenosine (m6A) modification post-transcriptionally stabilizes TGFB2 mRNA; TGFB2 then upregulates SREBF1 and downstream lipogenic enzymes via PI3K-AKT signaling to promote lipid accumulation and gemcitabine resistance in pancreatic ductal adenocarcinoma.","method":"RNA-seq on gemcitabine-resistant PDAC cells, bioinformatic analysis, m6A modification assays, TGFB2 silencing, lipidomic profiling, PI3K/AKT pathway inhibition, PDX mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A stabilization mechanism with lipid pathway placement demonstrated in PDX model, single lab with multiple methods","pmids":["38914663"],"is_preprint":false},{"year":2024,"finding":"Heterozygous mutations in the straitjacket subdomain of the latency-associated peptide (LAP) of pro-TGF-β2 cause Camurati-Engelmann disease type II by disrupting LAP conformation, reducing TGF-β2 inactivation, and increasing TGF-β2/SMAD signaling activity. iPS-cell-derived osteogenic differentiation from a CED2 patient showed significantly enhanced ossification.","method":"Exome sequencing, structural simulations of mutant LAPs, TGF-β2/SMAD signaling activity assay, in vitro osteogenic differentiation from CED2 patient-derived iPS cells","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — structural simulation plus functional signaling assay plus patient-derived iPSC differentiation, single lab","pmids":["39014191"],"is_preprint":false},{"year":2025,"finding":"TGFB2 signals through TGFBR3 (betaglycan) for SMC differentiation in a manner distinct from other TGFβ isoforms. TGFB2 haploinsufficiency (TGFB2KO/+) impairs differentiation of second heart field-derived SMCs, and TGFBR3KO/KO prevents molecular rescue of TGFB2KO/+ by exogenous TGFB2 supplementation, demonstrating TGFBR3 dependence in TGFB2-mediated SMC differentiation.","method":"hiPSC-derived SMC differentiation, CRISPR/Cas9 gene editing, siRNA experiments, 3D SMC tissue ring constructs, human aortic tissue analysis","journal":"Stem cells translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via TGFBR3KO rescue experiment demonstrates receptor dependence, single lab with multiple orthogonal methods","pmids":["40139558"],"is_preprint":false},{"year":2025,"finding":"Histone H3K18 lactylation at the TGFB2 promoter (mediated by P300 and GCN5 as candidate transferases) upregulates TGFB2 expression in pressure-overloaded hearts; cardiac-specific Tgfb2 knockdown reversed the prohypertrophic effects, while Tgfb2 overexpression promoted cardiomyocyte hypertrophy via PI3K/AKT/mTOR signaling.","method":"CUT&TAG, ChIP-qPCR, coimmunoprecipitation (for transferases), nascent RNA-seq, AAV-shRNA knockdown, lentiviral overexpression, pharmacological PI3K/AKT inhibition, mouse transverse aortic constriction model","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter-specific epigenetic modification linked to TGFB2 expression and functional hypertrophy phenotype with rescue, single lab","pmids":["41376590"],"is_preprint":false},{"year":2023,"finding":"NFATc1 regulates TGFB2 transcription in trabecular meshwork (TM) cells in a cell-cycle-dependent manner: dexamethasone-induced TGFB2 mRNA upregulation occurs in proliferating but not quiescent TM cells, and is inhibited by NFATc1 inhibitors (cyclosporine A or 11R-VIVIT).","method":"NFATc1 inhibition (cyclosporine A, 11R-VIVIT), cell cycle arrest by contact inhibition or serum starvation, RT-qPCR, Ki-67/p21 cell cycle markers","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition of transcription factor with specific phenotypic readout, two independent inhibitors confirm mechanism, single lab","pmids":["36766846"],"is_preprint":false},{"year":2019,"finding":"A ~100 bp enhancer region downstream of TGFB2 (containing variant rs1690789) contacts the TGFB2 promoter in human lung fibroblasts as shown by chromatin conformation capture; CRISPR/Cas9 deletion of this region decreased TGFB2 expression, establishing a regulatory mechanism linking a GWAS variant to TGFB2 expression in fibroblasts.","method":"GWAS, chromatin conformation capture (3C), CRISPR/Cas9 targeted deletion in primary human lung fibroblasts, eQTL analysis","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — CRISPR deletion plus 3C confirmation, single lab, functional reduction of TGFB2 expression demonstrated","pmids":["31343404"],"is_preprint":false},{"year":2022,"finding":"TGFB2 secreted by oocytes induces cumulus expansion through TGFBR1/TGFBR2-SMAD2/3 signaling in cumulus cells; TGFB2 increased expression of expansion-related genes in oocytectomized complexes in the presence of EGF, and this effect was blocked by TGF-β signaling inhibitor SD208 or by Tgfbr2 depletion in granulosa cells.","method":"Oocytectomized (OOX) complex culture, exogenous TGFB2 supplementation, SD208 inhibitor treatment, Tgfbr2-specific conditional knockout mice (Zp3-Cre and conditional Cre in granulosa cells), RT-qPCR","journal":"Molecular reproduction and development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic (receptor KO) and pharmacological (inhibitor) epistasis, single lab","pmids":["36128893"],"is_preprint":false},{"year":2010,"finding":"TGF-β2 confers amoeboid-like motility on Theileria-infected leukocytes through a transcription-independent mechanism involving cytoskeletal remodeling via Rho kinase (ROCK) activation; exogenous TGF-β2 rescued invasiveness of attenuated vaccine lines, and TGF-β2 levels correlated with increased actin dynamics in lamellipodia and podosomal structures.","method":"Exogenous TGF-β2 rescue experiments, fluorescence microscopy, time-lapse video microscopy for actin dynamics, ROCK pathway analysis","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — rescue with exogenous ligand plus live imaging of cytoskeletal changes, single lab with multiple orthogonal methods","pmids":["21124992"],"is_preprint":false},{"year":2021,"finding":"β-cell miR-21 directly targets and represses Tgfb2 and Smad2 mRNAs (confirmed by pulldown and luciferase assays), leading to reduced β-cell identity markers and glucose-stimulated insulin secretion in both in vitro and in vivo zebrafish and mouse models.","method":"RT-PCR, immunoblot, pulldown assay, luciferase assay, transgenic zebrafish and mouse models of β-cell-specific pre-miR-21 overexpression","journal":"Molecular metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — validated by pulldown and luciferase with in vivo confirmation in two species, single lab","pmids":["34246804"],"is_preprint":false},{"year":2025,"finding":"SMC-specific Tgfb2 conditional knockout in mice causes rapidly progressive thoracic aortic aneurysms with dissection and rupture. Loss of SMC-derived TGFβ2 suppresses canonical SMAD2/3 phosphorylation, activates non-canonical MAPK (p38 and ERK1/2) signaling, and causes SMC de-differentiation (reduced Acta2, Myh11) with ECM disorganization (elastic fiber fragmentation, increased collagen/proteoglycans).","method":"Tamoxifen-inducible SMC-specific Cre (Myh11CreERT2), ROSA lineage reporter, histological/morphometric analyses, western blotting for SMAD2/3, p38, ERK1/2, gene expression profiling","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional cell-type-specific KO with molecular signaling readouts, preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.10.01.679917"],"is_preprint":true},{"year":1997,"finding":"TGF-β2 secreted by glioma cells decreases TNF-induced VCAM-1 expression on glioma cells and brain-derived endothelial cells; glioma supernatant alone reproduced this effect on CNS endothelial cells in co-culture.","method":"Co-culture of A-172 glioma cells with CNS endothelial cells, VCAM-1 expression assay, glioma supernatant experiments","journal":"Journal of neuroimmunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single method type (expression assay in co-culture), no molecular mechanism of VCAM-1 suppression established","pmids":["9058771"],"is_preprint":false},{"year":2025,"finding":"FTO demethylates m6A modifications on TGFB2 mRNA in human BMSCs, increasing TGFB2 expression and promoting osteogenic differentiation; TGFB2 knockdown inhibited osteogenic differentiation downstream of FTO.","method":"m6A-seq, FTO knockdown by shRNA, TGFB2 knockdown, osteogenic differentiation assays","journal":"Oral diseases","confidence":"Low","confidence_rationale":"Tier 3 / Weak — m6A-seq identifies modification site, but mechanistic link between FTO demethylation and TGFB2 function relies on KD phenotype alone, single lab","pmids":["40127138"],"is_preprint":false},{"year":2025,"finding":"TIPE activates the P38 MAPK signaling pathway in colorectal cancer cells, leading to increased TGFB2 expression and secretion, which then acts on extracellular macrophages to induce M2 polarization, creating a feedback loop enhancing CRC malignant behavior.","method":"TIPE overexpression/knockdown, western blot for P38 MAPK, TGFB2 ELISA, macrophage polarization assays, animal experiments","journal":"Journal of leukocyte biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — signaling pathway placement via overexpression/knockdown, single lab, no direct biochemical reconstitution of TIPE-P38-TGFB2 axis","pmids":["40391468"],"is_preprint":false},{"year":2025,"finding":"RUNX1 promotes cervical cancer cell proliferation by upregulating TGFB2 expression, which activates the MAPK pathway; TGFB2 inhibition impaired MAPK pathway activation and reversed the proliferative effects of RUNX1 overexpression.","method":"RUNX1 overexpression/knockdown, TGFB2 inhibition, MAPK pathway western blot, cell cycle and proliferation assays","journal":"Scientific reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement by rescue experiment, single lab, mechanism of RUNX1 regulation of TGFB2 transcription not directly demonstrated","pmids":["39747496"],"is_preprint":false},{"year":2025,"finding":"TGFB2 knockdown in H9c2 cells subjected to oxygen-glucose deprivation promoted viability and inhibited apoptosis, reducing cleaved Caspase-3/Caspase-3 and Bax protein levels while increasing Bcl-2, implicating TGFB2 in cardiomyocyte apoptosis signaling in ischemia.","method":"TGFB2 knockdown, CCK-8 assay, flow cytometry for apoptosis, western blot for caspase-3, Bax, Bcl-2","journal":"Cardiovascular toxicology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method type (KD in cell line) with apoptosis readout, no upstream pathway placement, single lab","pmids":["40080329"],"is_preprint":false},{"year":2023,"finding":"TCF12 directly binds the TGFB2 promoter and activates TGFB2 transcription (established by ChIP and dual-luciferase reporter assay), promoting melanoma cell proliferation and metastasis downstream.","method":"RNA-seq, qPCR, immunoblotting, ChIP, dual-luciferase reporter assay, subcutaneous tumor formation assay","journal":"Cancers","confidence":"Low","confidence_rationale":"Tier 3 / Weak — ChIP and luciferase confirm direct promoter binding, but downstream signaling mechanism not fully elucidated; single lab","pmids":["37760480"],"is_preprint":false},{"year":2025,"finding":"STAT2 and SMAD3 are upstream transcription factors for TGFB2 in chicken granulosa cells: DNA pull-down and mass spectrometry identified STAT2 binding to the TGFB2 promoter, and SCENIC single-cell network analysis confirmed this regulatory interaction; the JAK/STAT-TGFB2-SMAD3 axis mediates granulosa cell degeneration during follicular atresia.","method":"DNA pull-down assay, mass spectrometry, SCENIC analysis of single-cell RNA sequencing data, ChIP validation","journal":"Poultry science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — DNA pull-down in chicken cells identifies binding but functional consequence inferred rather than directly tested; ortholog work in avian, single lab","pmids":["40902342"],"is_preprint":false}],"current_model":"TGFB2 encodes a secreted TGF-β ligand that signals canonically through TGFBR1/TGFBR2 (and distinctively through TGFBR3 in aortic root smooth muscle cells) to activate SMAD2/3 phosphorylation, promoting SMC differentiation, ECM homeostasis, EMT, and cell proliferation arrest; haploinsufficiency paradoxically upregulates compensatory TGF-β signaling in aortic tissue causing aneurysm, while gain-of-LAP mutations increase ligand activation causing Camurati-Engelmann disease; TGFB2 expression is regulated at multiple levels including by transcription factors (ΔNp63α, NFATc1, HOXA10, RUNX1, TCF12), epigenetic mechanisms (NF-κB/BRD4-dependent enhancer activation in SSc, histone H3K18 lactylation, FTO-mediated m6A demethylation), and non-coding RNAs, with downstream signaling through SMAD pathways as well as non-canonical RHOA and MAPK cascades."},"narrative":{"mechanistic_narrative":"TGFB2 encodes a secreted TGF-β ligand that signals through TGF-β receptors to activate SMAD2/3 phosphorylation, controlling smooth-muscle-cell differentiation, extracellular-matrix homeostasis, epithelial-to-mesenchymal transition, and cell-proliferation arrest [PMID:bio_10.1101_2025.10.01.679917, PMID:36128893]. In the aorta, TGFB2 haploinsufficiency causes thoracic aortic root aneurysm, and affected tissue paradoxically shows increased canonical and non-canonical TGF-β signaling and elevated TGF-β2 protein, consistent with an initial drop in cellular ligand triggering a secondary compensatory upregulation [PMID:22772368, PMID:22772371]. SMC-specific loss of TGFB2 reproduces this phenotype: it suppresses SMAD2/3 phosphorylation, activates non-canonical p38 and ERK1/2 MAPK signaling, drives SMC de-differentiation, and disorganizes the ECM [PMID:bio_10.1101_2025.10.01.679917]. TGFB2 acts in a distinctly isoform-specific manner during SMC differentiation, requiring TGFBR3 (betaglycan) as receptor, such that exogenous TGFB2 cannot rescue differentiation in the absence of TGFBR3 [PMID:40139558]. Conversely, gain-of-function mutations in the latency-associated peptide straitjacket subdomain of pro-TGF-β2 reduce ligand inactivation and increase TGF-β2/SMAD signaling, causing Camurati-Engelmann disease type II with enhanced ossification [PMID:39014191]. Beyond development and vascular biology, TGFB2 mediates oocyte-driven cumulus expansion via TGFBR1/TGFBR2-SMAD2/3 [PMID:36128893], enforces a profibrotic state in systemic-sclerosis fibroblasts through autocrine signaling [PMID:31217334], and can act through non-canonical RHOA to arrest proliferation in squamous carcinoma [PMID:30232004]. TGFB2 expression is tightly controlled by transcription factors (ΔNp63α repression, HOXA10, NFATc1) and by epigenetic and RNA-level mechanisms including enhancer activation, m6A modification, and histone H3K18 lactylation [PMID:30232004, PMID:33563300, PMID:31217334, PMID:38914663, PMID:41376590].","teleology":[{"year":2012,"claim":"Established that TGFB2 dosage is critical for aortic integrity and revealed the counterintuitive principle that loss-of-function ligand mutations elevate tissue TGF-β signaling.","evidence":"Tgfb2+/- mouse models plus human linkage/exome sequencing with aortic tissue immunostaining and signaling western blots","pmids":["22772368","22772371"],"confidence":"High","gaps":["Molecular basis of the compensatory upregulation not defined","Cell type driving the paradoxical signaling increase not resolved at this stage"]},{"year":2018,"claim":"Placed TGFB2 downstream of a transcriptional repressor and defined a non-canonical effector branch, showing TGFB2 induction activates RHOA to enforce proliferation arrest.","evidence":"CRISPR screen, ΔNp63α knockdown, ectopic TGFB2 expression, neutralizing antibody, and RHOA activity assays in squamous carcinoma cells","pmids":["30232004"],"confidence":"High","gaps":["Receptor mediating RHOA activation not identified","Generalizability beyond SCC unknown"]},{"year":2019,"claim":"Demonstrated cis-regulatory control of TGFB2 expression by enhancer elements, linking a GWAS variant and an epigenetically maintained enhancer to autocrine profibrotic signaling.","evidence":"3C/chromatin conformation capture, CRISPR/Cas9 enhancer deletion in lung fibroblasts, ATAC-seq, CRISPRi, and NF-κB/BRD4 inhibition in patient skin explants","pmids":["31343404","31217334"],"confidence":"High","gaps":["Trans factors binding the enhancer only partially defined","Whether enhancer regulation operates in vascular tissue not tested"]},{"year":2016,"claim":"Showed TGFB2 has isoform-specific developmental functions, with RUNX1-dependent TGFB2 (not TGFB1) signaling driving motility and EMT during mesendodermal differentiation.","evidence":"RUNX1 siRNA depletion in hESCs with isoform-specific rescue by exogenous TGFB2 versus TGFB1","pmids":["27720906"],"confidence":"Medium","gaps":["Mechanism of isoform specificity at the receptor level not addressed","Direct RUNX1 binding to TGFB2 locus not shown here"]},{"year":2022,"claim":"Defined a physiological paracrine role for oocyte-secreted TGFB2 acting through canonical receptors to drive cumulus expansion.","evidence":"Oocytectomized complex culture with exogenous TGFB2, SD208 inhibitor, and Tgfbr2 conditional knockout in granulosa cells","pmids":["36128893"],"confidence":"Medium","gaps":["Relative contribution versus other oocyte factors not quantified","SMAD-target genes for expansion not fully enumerated"]},{"year":2024,"claim":"Connected LAP structural integrity to ligand bioavailability, showing straitjacket-subdomain mutations reduce latency and increase signaling to cause Camurati-Engelmann disease type II.","evidence":"Exome sequencing, structural simulations of mutant LAPs, SMAD signaling assay, and osteogenic differentiation of CED2 patient iPS cells","pmids":["39014191"],"confidence":"Medium","gaps":["In vivo skeletal phenotype not modeled genetically","Quantitative activation kinetics of mutant LAP not measured"]},{"year":2025,"claim":"Resolved the receptor identity for TGFB2 in SMC differentiation, establishing TGFBR3 dependence that distinguishes TGFB2 from other isoforms.","evidence":"hiPSC-derived SMC differentiation, CRISPR/Cas9 and siRNA, 3D tissue rings, and TGFBR3KO epistasis blocking exogenous-TGFB2 rescue","pmids":["40139558"],"confidence":"Medium","gaps":["How TGFBR3 couples TGFB2 to canonical SMAD output not detailed","Relevance to the aneurysm paradox not directly tested"]},{"year":2025,"claim":"Provided cell-autonomous genetic confirmation that SMC-derived TGFB2 maintains aortic SMC identity and ECM, with loss shifting signaling toward non-canonical MAPK.","evidence":"SMC-specific tamoxifen-inducible Tgfb2 knockout mice with histomorphometry and SMAD2/3, p38, ERK1/2 western blots (preprint)","pmids":["bio_10.1101_2025.10.01.679917"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Causal ordering of SMAD loss versus MAPK gain not dissected"]},{"year":2025,"claim":"Extended TGFB2 transcriptional regulation to metabolic-epigenetic inputs, linking H3K18 lactylation at the promoter to pathological cardiac hypertrophy.","evidence":"CUT&TAG, ChIP-qPCR, nascent RNA-seq, AAV-shRNA knockdown/overexpression, and PI3K/AKT inhibition in a transverse aortic constriction mouse model","pmids":["41376590"],"confidence":"Medium","gaps":["Definitive transferase responsible for promoter lactylation not isolated","Reconciliation with protective vascular roles of TGFB2 unaddressed"]},{"year":null,"claim":"How a single ligand integrates receptor choice (TGFBR1/2 versus TGFBR3), canonical SMAD versus non-canonical RHOA/MAPK branches, and tissue-specific dosage sensitivity to yield context-dependent outcomes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking the aortic loss-of-function paradox to the CED2 gain-of-function mechanism","Determinants of canonical versus non-canonical branch selection unknown","Structural basis of TGFBR3-dependent isoform specificity uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[8,12,7]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[15,2]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[5,12,15]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[15,12,2]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,7]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[15]}],"complexes":[],"partners":["TGFBR1","TGFBR2","TGFBR3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P61812","full_name":"Transforming growth factor beta-2 proprotein","aliases":["Cetermin","Glioblastoma-derived T-cell suppressor factor","G-TSF"],"length_aa":414,"mass_kda":47.7,"function":"Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix (By similarity). Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 (By similarity) Multifunctional protein that regulates various processes such as angiogenesis and heart development (PubMed:22772368, PubMed:22772371). Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix (By similarity). At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus (By similarity). Once activated following release of LAP, TGF-beta-2 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (By similarity)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P61812/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TGFB2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TGFB2","total_profiled":1310},"omim":[{"mim_id":"621228","title":"LONG INTERGENIC NONCODING RNA 1013; LINC01013","url":"https://www.omim.org/entry/621228"},{"mim_id":"619018","title":"MICRO RNA 30B; MIR30B","url":"https://www.omim.org/entry/619018"},{"mim_id":"615589","title":"OTOSCLEROSIS 10; OTSC10","url":"https://www.omim.org/entry/615589"},{"mim_id":"615582","title":"LOEYS-DIETZ SYNDROME 5; LDS5","url":"https://www.omim.org/entry/615582"},{"mim_id":"614816","title":"LOEYS-DIETZ SYNDROME 4; LDS4","url":"https://www.omim.org/entry/614816"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TGFB2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P61812","domains":[{"cath_id":"2.60.120.970","chopping":"101-111_123-255_275-284","consensus_level":"high","plddt":88.1508,"start":101,"end":284}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P61812","model_url":"https://alphafold.ebi.ac.uk/files/AF-P61812-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P61812-F1-predicted_aligned_error_v6.png","plddt_mean":80.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TGFB2","jax_strain_url":"https://www.jax.org/strain/search?query=TGFB2"},"sequence":{"accession":"P61812","fasta_url":"https://rest.uniprot.org/uniprotkb/P61812.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P61812/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P61812"}},"corpus_meta":[{"pmid":"22772368","id":"PMC_22772368","title":"Loss-of-function mutations in TGFB2 cause a syndromic presentation of thoracic aortic aneurysm.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22772368","citation_count":362,"is_preprint":false},{"pmid":"22772371","id":"PMC_22772371","title":"TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22772371","citation_count":295,"is_preprint":false},{"pmid":"29392890","id":"PMC_29392890","title":"A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29392890","citation_count":135,"is_preprint":false},{"pmid":"26565952","id":"PMC_26565952","title":"A new microRNA signal pathway regulated by long noncoding RNA TGFB2-OT1 in autophagy and inflammation of vascular endothelial cells.","date":"2015","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/26565952","citation_count":134,"is_preprint":false},{"pmid":"9003904","id":"PMC_9003904","title":"Studies of the candidate genes TGFB2, MSX1, TGFA, and TGFB3 in the etiology of cleft lip and palate in the Philippines.","date":"1997","source":"The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association","url":"https://pubmed.ncbi.nlm.nih.gov/9003904","citation_count":115,"is_preprint":false},{"pmid":"33563300","id":"PMC_33563300","title":"HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33563300","citation_count":110,"is_preprint":false},{"pmid":"21124992","id":"PMC_21124992","title":"TGF-b2 induction regulates invasiveness of Theileria-transformed leukocytes and disease susceptibility.","date":"2010","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/21124992","citation_count":60,"is_preprint":false},{"pmid":"31217334","id":"PMC_31217334","title":"Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis.","date":"2019","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31217334","citation_count":54,"is_preprint":false},{"pmid":"26551255","id":"PMC_26551255","title":"miR-599 Inhibits Vascular Smooth Muscle Cells Proliferation and Migration by Targeting TGFB2.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26551255","citation_count":47,"is_preprint":false},{"pmid":"36126099","id":"PMC_36126099","title":"TGFB2-AS1 inhibits triple-negative breast cancer progression via interaction with SMARCA4 and regulating its targets TGFB2 and SOX2.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36126099","citation_count":46,"is_preprint":false},{"pmid":"30232004","id":"PMC_30232004","title":"ΔNp63α Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30232004","citation_count":43,"is_preprint":false},{"pmid":"34237642","id":"PMC_34237642","title":"Cadmium promotes apoptosis and inflammation via the circ08409/miR-133a/TGFB2 axis in bovine mammary epithelial cells and mouse mammary gland.","date":"2021","source":"Ecotoxicology and environmental safety","url":"https://pubmed.ncbi.nlm.nih.gov/34237642","citation_count":34,"is_preprint":false},{"pmid":"33760169","id":"PMC_33760169","title":"miR‑454‑3p inhibits non‑small cell lung cancer cell proliferation and metastasis by targeting TGFB2.","date":"2021","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33760169","citation_count":30,"is_preprint":false},{"pmid":"31533040","id":"PMC_31533040","title":"The TGFB2-AS1 lncRNA Regulates TGF-β Signaling by Modulating Corepressor Activity.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31533040","citation_count":30,"is_preprint":false},{"pmid":"32661705","id":"PMC_32661705","title":"MicroRNA-148a-3p alleviates high glucose-induced diabetic retinopathy by targeting TGFB2 and FGF2.","date":"2020","source":"Acta diabetologica","url":"https://pubmed.ncbi.nlm.nih.gov/32661705","citation_count":30,"is_preprint":false},{"pmid":"32388013","id":"PMC_32388013","title":"TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer.","date":"2020","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32388013","citation_count":27,"is_preprint":false},{"pmid":"25163805","id":"PMC_25163805","title":"Further delineation of Loeys-Dietz syndrome type 4 in a family with mild vascular involvement and a TGFB2 splicing mutation.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25163805","citation_count":27,"is_preprint":false},{"pmid":"38914663","id":"PMC_38914663","title":"N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38914663","citation_count":26,"is_preprint":false},{"pmid":"31343404","id":"PMC_31343404","title":"Identification of an emphysema-associated genetic variant near TGFB2 with regulatory effects in lung fibroblasts.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/31343404","citation_count":26,"is_preprint":false},{"pmid":"25813153","id":"PMC_25813153","title":"Tumor suppressive microRNA-200a inhibits renal cell carcinoma development by directly targeting TGFB2.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25813153","citation_count":25,"is_preprint":false},{"pmid":"33816780","id":"PMC_33816780","title":"The lncRNA DLGAP1-AS1/miR-149-5p/TGFB2 axis contributes to colorectal cancer progression and 5-FU resistance by regulating smad2 pathway.","date":"2021","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/33816780","citation_count":23,"is_preprint":false},{"pmid":"27720906","id":"PMC_27720906","title":"Transient RUNX1 Expression during Early Mesendodermal Differentiation of hESCs Promotes Epithelial to Mesenchymal Transition through TGFB2 Signaling.","date":"2016","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27720906","citation_count":23,"is_preprint":false},{"pmid":"23439295","id":"PMC_23439295","title":"Differential expression of GDF9, TGFB1, TGFB2 and TGFB3 in porcine oocytes isolated from follicles of different size before and after culture in vitro.","date":"2013","source":"Acta veterinaria Hungarica","url":"https://pubmed.ncbi.nlm.nih.gov/23439295","citation_count":22,"is_preprint":false},{"pmid":"17431704","id":"PMC_17431704","title":"Investigation of TGFB2 as a candidate gene in multiple sclerosis and Parkinson's disease.","date":"2007","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/17431704","citation_count":22,"is_preprint":false},{"pmid":"8095486","id":"PMC_8095486","title":"Linkage localization of TGFB2 and the human homeobox gene HLX1 to chromosome 1q.","date":"1993","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8095486","citation_count":21,"is_preprint":false},{"pmid":"25046559","id":"PMC_25046559","title":"Whole exome sequencing for the identification of a new mutation in TGFB2 involved in a familial case of non-syndromic aortic disease.","date":"2014","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25046559","citation_count":20,"is_preprint":false},{"pmid":"24440784","id":"PMC_24440784","title":"Loeys-Dietz syndrome type 4, caused by chromothripsis, involving the TGFB2 gene.","date":"2014","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/24440784","citation_count":16,"is_preprint":false},{"pmid":"34362313","id":"PMC_34362313","title":"Association of CASC18/miR-20a-3p/TGFB2 ceRNA axis with occult lymph node metastasis in tongue squamous cell carcinoma.","date":"2021","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/34362313","citation_count":15,"is_preprint":false},{"pmid":"34246804","id":"PMC_34246804","title":"β-Cell pre-mir-21 induces dysfunction and loss of cellular identity by targeting transforming growth factor beta 2 (Tgfb2) and Smad family member 2 (Smad2) mRNAs.","date":"2021","source":"Molecular metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/34246804","citation_count":15,"is_preprint":false},{"pmid":"8454288","id":"PMC_8454288","title":"Linkage of Van der Woude syndrome (VWS) to REN and exclusion of the candidate gene TGFB2 from the disease locus in a large pedigree.","date":"1993","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8454288","citation_count":15,"is_preprint":false},{"pmid":"24299181","id":"PMC_24299181","title":"Association of single nucleotide polymorphism of GHSR and TGFB2 genes with growth and body composition traits in sire and dam lines of a broiler chicken.","date":"2014","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24299181","citation_count":14,"is_preprint":false},{"pmid":"20477792","id":"PMC_20477792","title":"A novel 62-bp indel mutation in the promoter region of transforming growth factor-beta 2 (TGFB2) gene is associated with body weight in chickens.","date":"2011","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20477792","citation_count":14,"is_preprint":false},{"pmid":"9058771","id":"PMC_9058771","title":"TGF-B2 and soluble p55 TNFR modulate VCAM-1 expression in glioma cells and brain derived endothelial cells.","date":"1997","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/9058771","citation_count":14,"is_preprint":false},{"pmid":"24193348","id":"PMC_24193348","title":"A 1-bp duplication in TGFB2 in three family members with a syndromic form of thoracic aortic aneurysm.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/24193348","citation_count":13,"is_preprint":false},{"pmid":"34828300","id":"PMC_34828300","title":"miR-301a-5p Regulates TGFB2 during Chicken Spermatogenesis.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34828300","citation_count":11,"is_preprint":false},{"pmid":"40139558","id":"PMC_40139558","title":"TGFBR3 dependent mechanism of TGFB2 in smooth muscle cell differentiation and implications for TGFB2-related aortic aneurysm.","date":"2025","source":"Stem cells translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40139558","citation_count":9,"is_preprint":false},{"pmid":"28900109","id":"PMC_28900109","title":"Region-specific differential corneal and scleral mRNA expressions of MMP2, TIMP2, and TGFB2 in highly myopic-astigmatic chicks.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28900109","citation_count":9,"is_preprint":false},{"pmid":"36941998","id":"PMC_36941998","title":"LncRNA TGFB2-OT1 Promotes Progression and Angiogenesis in Hepatocellular Carcinoma by Dephosphorylating β-Catenin.","date":"2023","source":"Journal of hepatocellular carcinoma","url":"https://pubmed.ncbi.nlm.nih.gov/36941998","citation_count":7,"is_preprint":false},{"pmid":"36128893","id":"PMC_36128893","title":"Oocyte-secreted factor TGFB2 enables mouse cumulus cell expansion in vitro.","date":"2022","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/36128893","citation_count":7,"is_preprint":false},{"pmid":"31066006","id":"PMC_31066006","title":"Down-regulation expression of TGFB2-AS1 inhibits the proliferation, migration, invasion and induces apoptosis in HepG2 cells.","date":"2019","source":"Genes & genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31066006","citation_count":7,"is_preprint":false},{"pmid":"37760480","id":"PMC_37760480","title":"TCF12 Activates TGFB2 Expression to Promote the Malignant Progression of Melanoma.","date":"2023","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/37760480","citation_count":6,"is_preprint":false},{"pmid":"34792732","id":"PMC_34792732","title":"Up-regulation of TGFBI and TGFB2 in the plasma of gestational diabetes mellitus patients and its clinical significance.","date":"2021","source":"Irish journal of medical science","url":"https://pubmed.ncbi.nlm.nih.gov/34792732","citation_count":6,"is_preprint":false},{"pmid":"36670490","id":"PMC_36670490","title":"Hsa_circ_0001326 inhibited the proliferation, migration, and invasion of trophoblast cells via miR-145-5p/TGFB2 axis.","date":"2023","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/36670490","citation_count":6,"is_preprint":false},{"pmid":"36766846","id":"PMC_36766846","title":"NFATc1 Regulation of Dexamethasone-Induced TGFB2 Expression Is Cell Cycle Dependent in Trabecular Meshwork Cells.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/36766846","citation_count":5,"is_preprint":false},{"pmid":"37567360","id":"PMC_37567360","title":"The hsa_circ_0004805/hsa_miR-149-5p/TGFB2 axis plays critical roles in the pathophysiology of diabetic retinopathy in vitro and in vivo.","date":"2023","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/37567360","citation_count":5,"is_preprint":false},{"pmid":"30805402","id":"PMC_30805402","title":"Significant Association and Increased Risk of Primary Open Angle Glaucoma with TGFB2 Rs991967 Gene Polymorphism in North Eastern Iranian Patients.","date":"2019","source":"Reports of biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30805402","citation_count":5,"is_preprint":false},{"pmid":"34680857","id":"PMC_34680857","title":"Differential Diagnosis between Marfan Syndrome and Loeys-Dietz Syndrome Type 4: A Novel Chromosomal Deletion Covering TGFB2.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34680857","citation_count":5,"is_preprint":false},{"pmid":"41376590","id":"PMC_41376590","title":"Histone Lactylation Promotes Pressure Overload-Induced Cardiac Hypertrophy and Heart Failure by Regulating TGFB2 Expression.","date":"2025","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/41376590","citation_count":4,"is_preprint":false},{"pmid":"39747496","id":"PMC_39747496","title":"RUNX1 promotes proliferation of cervical cancer through TGFB2-MAPK pathway.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/39747496","citation_count":4,"is_preprint":false},{"pmid":"33996791","id":"PMC_33996791","title":"Association of Myopia and Genetic Variants of TGFB2-AS1 and TGFBR1 in the TGF-β Signaling Pathway: A Longitudinal Study in Chinese School-Aged Children.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33996791","citation_count":4,"is_preprint":false},{"pmid":"32774737","id":"PMC_32774737","title":"LncRNA TGFB2-AS1 regulates lung adenocarcinoma progression via act as a sponge for miR-340-5p to target EDNRB expression.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32774737","citation_count":4,"is_preprint":false},{"pmid":"39014191","id":"PMC_39014191","title":"Heterozygous mutations in the straitjacket region of the latency-associated peptide domain of TGFB2 cause Camurati-Engelmann disease type II.","date":"2024","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39014191","citation_count":4,"is_preprint":false},{"pmid":"39293448","id":"PMC_39293448","title":"Congenital microcoria deletion in mouse links Sox21 dysregulation to disease and suggests a role for TGFB2 in glaucoma and myopia.","date":"2024","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39293448","citation_count":3,"is_preprint":false},{"pmid":"27698889","id":"PMC_27698889","title":"TGFB2 and BCL2L11 methylation in male laryngeal cancer patients.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27698889","citation_count":3,"is_preprint":false},{"pmid":"35426477","id":"PMC_35426477","title":"Loeys-Dietz syndrome caused by 1q41 deletion including TGFB2 is associated with a neurodevelopmental phenotype.","date":"2022","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/35426477","citation_count":3,"is_preprint":false},{"pmid":"9269043","id":"PMC_9269043","title":"The antibody-neutralisation of PDGF, CSF-1, TGFb2,3, EGF and EGF-receptor in utero in pre-implantation mice.","date":"1997","source":"Upsala journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/9269043","citation_count":3,"is_preprint":false},{"pmid":"38305450","id":"PMC_38305450","title":"Dysregulation of the circRNA_0087207/miR-548c-3p/PLSR1-TGFB2 axis in Leber hereditary optic neuropathy in vitro.","date":"2024","source":"Journal of the Chinese Medical Association : JCMA","url":"https://pubmed.ncbi.nlm.nih.gov/38305450","citation_count":2,"is_preprint":false},{"pmid":"40391468","id":"PMC_40391468","title":"TIPE regulates TGFB2 expression and induces extracellular M2 polarization in CRC.","date":"2025","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/40391468","citation_count":1,"is_preprint":false},{"pmid":"40080329","id":"PMC_40080329","title":"Knockdown of TGFB2 Attenuates Ischemic Heart Failure by Inhibiting Apoptosis.","date":"2025","source":"Cardiovascular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/40080329","citation_count":1,"is_preprint":false},{"pmid":"32307099","id":"PMC_32307099","title":"Corneal thinning and cornea guttata in patients with mutations in TGFB2.","date":"2020","source":"Canadian journal of ophthalmology. Journal canadien d'ophtalmologie","url":"https://pubmed.ncbi.nlm.nih.gov/32307099","citation_count":1,"is_preprint":false},{"pmid":"40902342","id":"PMC_40902342","title":"TGFB2/IGFBP5 activated by transcription factors STAT2 and SMAD3 initiate granulosa cell degeneration and cause follicular atresia in chickens.","date":"2025","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/40902342","citation_count":1,"is_preprint":false},{"pmid":"27782106","id":"PMC_27782106","title":"A missense TGFB2 variant p.(Arg320Cys) causes a paradoxical and striking increase in aortic TGFB1/2 expression.","date":"2016","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/27782106","citation_count":1,"is_preprint":false},{"pmid":"41923885","id":"PMC_41923885","title":"Long non-coding RNA TGFB2-OT1 as a diagnostic biomarker and ceRNA regulator in rheumatoid arthritis.","date":"2026","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41923885","citation_count":0,"is_preprint":false},{"pmid":"40738046","id":"PMC_40738046","title":"Reduced level of BMI1 inhibits trophoblast proliferation and migration via the epigenetic enhancement of CSTA and TGFB2 in spontaneous abortion.","date":"2025","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/40738046","citation_count":0,"is_preprint":false},{"pmid":"41170304","id":"PMC_41170304","title":"A Novel Mutation of TGFB2 Gene Responsible of Loeys-Dietz 4 Syndrome.","date":"2025","source":"International medical case reports journal","url":"https://pubmed.ncbi.nlm.nih.gov/41170304","citation_count":0,"is_preprint":false},{"pmid":"42125524","id":"PMC_42125524","title":"Case report: Loeys-Dietz syndrome (TGFB2).","date":"2026","source":"European heart journal. Case reports","url":"https://pubmed.ncbi.nlm.nih.gov/42125524","citation_count":0,"is_preprint":false},{"pmid":"40127138","id":"PMC_40127138","title":"FTO Promotes Osteogenic Differentiation of Human BMSCs via Demethylation of TGFB2 m6A Modifications.","date":"2025","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40127138","citation_count":0,"is_preprint":false},{"pmid":"42031322","id":"PMC_42031322","title":"Doxorubicin-induced apoptosis and mitochondrial fission are promoted by LncRNA TGFB2-AS1 through BMP7/Smad signaling.","date":"2026","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/42031322","citation_count":0,"is_preprint":false},{"pmid":"41920409","id":"PMC_41920409","title":"Transcriptional repression of TGFB2-AS1 by GATA6 drives triple-negative breast cancer metastasis.","date":"2026","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/41920409","citation_count":0,"is_preprint":false},{"pmid":"41559906","id":"PMC_41559906","title":"Leukemia-derived exosomes induce immunosuppression of dendritic cell function via TGFB2-MRPL58 axis.","date":"2026","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/41559906","citation_count":0,"is_preprint":false},{"pmid":"41529022","id":"PMC_41529022","title":"A TGFB2/TNF-induced in vitro model of proliferative vitreoretinopathy (PVR) using ARPE-19 cells confirms nicotinamide as an inhibitor of EMT and VEGFA secretion.","date":"2026","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/41529022","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.01.679917","title":"Smooth Muscle Cell-Specific TGFβ2 Protects Against Thoracic Aortic Aneurysm and Dissection in Mice","date":"2025-10-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.01.679917","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.03.680228","title":"Zyxin Restricts Viral Fusion and Entry across Multiple Virus Families","date":"2025-10-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.03.680228","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.17.688818","title":"Vascular Basement Membrane Laminins Modulate Functional Zonation of Cerebral Microvessels","date":"2025-11-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.17.688818","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.22.677845","title":"Cardiomyocyte-expressed TGFβ signals to fibroblasts to program early heart maturation and adult myocyte identity","date":"2025-09-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.22.677845","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.30.662131","title":"Dissecting  <i>ARL15</i>  Function in Rheumatoid Arthritis: Insights from  <i>Ex Vivo</i>  and  <i>In Vitro</i>  Synovial Fibroblast Models","date":"2025-07-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.30.662131","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43735,"output_tokens":6194,"usd":0.112058,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14780,"output_tokens":3599,"usd":0.081937,"stage2_stop_reason":"end_turn"},"total_usd":0.193995,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2012,\n      \"finding\": \"Heterozygous loss-of-function mutations or deletions in TGFB2 cause aortic root aneurysm in Tgfb2+/- mice with biochemical evidence of increased canonical and noncanonical TGF-β signaling, indicating that TGFB2 haploinsufficiency paradoxically upregulates TGF-β signaling in aortic tissue.\",\n      \"method\": \"Genetic mouse model (Tgfb2+/- haploinsufficient mice), western blotting for signaling markers, compound mutant mice with Fbn1(C1039G/+)\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal genetic and biochemical evidence in both human patients and mouse models, replicated across two independent Nature Genetics papers in the same year\",\n      \"pmids\": [\"22772368\", \"22772371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TGFB2 haploinsufficiency (frameshift and nonsense mutations causing loss of function) predisposes to thoracic aortic aneurysm and dissection; paradoxically, aortic tissue from affected individuals shows increased TGF-β2 expression and immunostaining, suggesting an initial decrease in cellular TGF-β2 leads to a secondary compensatory increase.\",\n      \"method\": \"Genome-wide linkage analysis, whole-exome sequencing, Sanger sequencing, immunostaining of aortic tissue from affected individuals\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (linkage, sequencing, tissue immunostaining), replicated in independent cohort in companion paper\",\n      \"pmids\": [\"22772371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ΔNp63α transcriptionally represses TGFB2 expression; upon ΔNp63α depletion, TGFB2 is upregulated, which activates RHOA and induces cell cycle arrest in squamous cell carcinomas. Ectopic TGFB2 activates RHOA and impairs SCC proliferation, and TGFB2 neutralization restores cell proliferation during ΔNp63α depletion.\",\n      \"method\": \"Genome-wide CRISPR screen, RHOA activity assays, transcriptome analysis, ΔNp63α knockdown, ectopic TGFB2 expression, TGFB2 neutralizing antibody\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including CRISPR screen, rescue experiments with ectopic TGFB2 and neutralization, epistasis established\",\n      \"pmids\": [\"30232004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Constitutive activation of a TGFB2 enhancer, maintained through epigenetic memory (H3K27ac), drives autocrine TGFβ2 signaling and enforces a profibrotic synthetic state in SSc fibroblasts. NF-κB and BRD4 inhibition suppresses TGFB2 enhancer activity and reverses dermal fibrosis in patient skin explants.\",\n      \"method\": \"Chromatin accessibility profiling (ATAC-seq), transcriptome profiling, targeted epigenetic editing (CRISPRi), NF-κB and BRD4 inhibition, patient skin explants\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — targeted epigenetic editing plus functional phenotypic readout in patient explants, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"31217334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RUNX1 depletion in hESCs specifically compromises TGFB2 (but not TGFB1) signaling, impairing cell motility and epithelial-to-mesenchymal transition during mesendodermal differentiation. Reintroduction of TGFB2 (not TGFB1) rescues both decreased motility and deregulated epithelial marker expression caused by RUNX1 loss.\",\n      \"method\": \"RUNX1 depletion by siRNA, transcriptome profiling, cell motility assays, rescue experiments with exogenous TGFB2 and TGFB1\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific rescue experiment provides clear mechanistic placement, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27720906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HOXA10 binds to the TGFB2 promoter (shown by ChIP-qPCR), promotes TGFB2 transcription and secretion, thereby triggering TGFβ/Smad signaling with nuclear Smad2/3 accumulation, which in turn upregulates METTL3 expression and promotes EMT in gastric cancer cells. CoIP demonstrated Smad proteins mediate METTL3 expression.\",\n      \"method\": \"ChIP-qPCR, dual-luciferase reporter assay, CoIP, western blot, colorimetric m6A assay, in vivo lung metastasis rescue models\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-qPCR and CoIP with functional rescue in vivo, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33563300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"METTL14-mediated N6-methyladenosine (m6A) modification post-transcriptionally stabilizes TGFB2 mRNA; TGFB2 then upregulates SREBF1 and downstream lipogenic enzymes via PI3K-AKT signaling to promote lipid accumulation and gemcitabine resistance in pancreatic ductal adenocarcinoma.\",\n      \"method\": \"RNA-seq on gemcitabine-resistant PDAC cells, bioinformatic analysis, m6A modification assays, TGFB2 silencing, lipidomic profiling, PI3K/AKT pathway inhibition, PDX mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A stabilization mechanism with lipid pathway placement demonstrated in PDX model, single lab with multiple methods\",\n      \"pmids\": [\"38914663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Heterozygous mutations in the straitjacket subdomain of the latency-associated peptide (LAP) of pro-TGF-β2 cause Camurati-Engelmann disease type II by disrupting LAP conformation, reducing TGF-β2 inactivation, and increasing TGF-β2/SMAD signaling activity. iPS-cell-derived osteogenic differentiation from a CED2 patient showed significantly enhanced ossification.\",\n      \"method\": \"Exome sequencing, structural simulations of mutant LAPs, TGF-β2/SMAD signaling activity assay, in vitro osteogenic differentiation from CED2 patient-derived iPS cells\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — structural simulation plus functional signaling assay plus patient-derived iPSC differentiation, single lab\",\n      \"pmids\": [\"39014191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TGFB2 signals through TGFBR3 (betaglycan) for SMC differentiation in a manner distinct from other TGFβ isoforms. TGFB2 haploinsufficiency (TGFB2KO/+) impairs differentiation of second heart field-derived SMCs, and TGFBR3KO/KO prevents molecular rescue of TGFB2KO/+ by exogenous TGFB2 supplementation, demonstrating TGFBR3 dependence in TGFB2-mediated SMC differentiation.\",\n      \"method\": \"hiPSC-derived SMC differentiation, CRISPR/Cas9 gene editing, siRNA experiments, 3D SMC tissue ring constructs, human aortic tissue analysis\",\n      \"journal\": \"Stem cells translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via TGFBR3KO rescue experiment demonstrates receptor dependence, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"40139558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Histone H3K18 lactylation at the TGFB2 promoter (mediated by P300 and GCN5 as candidate transferases) upregulates TGFB2 expression in pressure-overloaded hearts; cardiac-specific Tgfb2 knockdown reversed the prohypertrophic effects, while Tgfb2 overexpression promoted cardiomyocyte hypertrophy via PI3K/AKT/mTOR signaling.\",\n      \"method\": \"CUT&TAG, ChIP-qPCR, coimmunoprecipitation (for transferases), nascent RNA-seq, AAV-shRNA knockdown, lentiviral overexpression, pharmacological PI3K/AKT inhibition, mouse transverse aortic constriction model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter-specific epigenetic modification linked to TGFB2 expression and functional hypertrophy phenotype with rescue, single lab\",\n      \"pmids\": [\"41376590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NFATc1 regulates TGFB2 transcription in trabecular meshwork (TM) cells in a cell-cycle-dependent manner: dexamethasone-induced TGFB2 mRNA upregulation occurs in proliferating but not quiescent TM cells, and is inhibited by NFATc1 inhibitors (cyclosporine A or 11R-VIVIT).\",\n      \"method\": \"NFATc1 inhibition (cyclosporine A, 11R-VIVIT), cell cycle arrest by contact inhibition or serum starvation, RT-qPCR, Ki-67/p21 cell cycle markers\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition of transcription factor with specific phenotypic readout, two independent inhibitors confirm mechanism, single lab\",\n      \"pmids\": [\"36766846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A ~100 bp enhancer region downstream of TGFB2 (containing variant rs1690789) contacts the TGFB2 promoter in human lung fibroblasts as shown by chromatin conformation capture; CRISPR/Cas9 deletion of this region decreased TGFB2 expression, establishing a regulatory mechanism linking a GWAS variant to TGFB2 expression in fibroblasts.\",\n      \"method\": \"GWAS, chromatin conformation capture (3C), CRISPR/Cas9 targeted deletion in primary human lung fibroblasts, eQTL analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — CRISPR deletion plus 3C confirmation, single lab, functional reduction of TGFB2 expression demonstrated\",\n      \"pmids\": [\"31343404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TGFB2 secreted by oocytes induces cumulus expansion through TGFBR1/TGFBR2-SMAD2/3 signaling in cumulus cells; TGFB2 increased expression of expansion-related genes in oocytectomized complexes in the presence of EGF, and this effect was blocked by TGF-β signaling inhibitor SD208 or by Tgfbr2 depletion in granulosa cells.\",\n      \"method\": \"Oocytectomized (OOX) complex culture, exogenous TGFB2 supplementation, SD208 inhibitor treatment, Tgfbr2-specific conditional knockout mice (Zp3-Cre and conditional Cre in granulosa cells), RT-qPCR\",\n      \"journal\": \"Molecular reproduction and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (receptor KO) and pharmacological (inhibitor) epistasis, single lab\",\n      \"pmids\": [\"36128893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TGF-β2 confers amoeboid-like motility on Theileria-infected leukocytes through a transcription-independent mechanism involving cytoskeletal remodeling via Rho kinase (ROCK) activation; exogenous TGF-β2 rescued invasiveness of attenuated vaccine lines, and TGF-β2 levels correlated with increased actin dynamics in lamellipodia and podosomal structures.\",\n      \"method\": \"Exogenous TGF-β2 rescue experiments, fluorescence microscopy, time-lapse video microscopy for actin dynamics, ROCK pathway analysis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rescue with exogenous ligand plus live imaging of cytoskeletal changes, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"21124992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"β-cell miR-21 directly targets and represses Tgfb2 and Smad2 mRNAs (confirmed by pulldown and luciferase assays), leading to reduced β-cell identity markers and glucose-stimulated insulin secretion in both in vitro and in vivo zebrafish and mouse models.\",\n      \"method\": \"RT-PCR, immunoblot, pulldown assay, luciferase assay, transgenic zebrafish and mouse models of β-cell-specific pre-miR-21 overexpression\",\n      \"journal\": \"Molecular metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — validated by pulldown and luciferase with in vivo confirmation in two species, single lab\",\n      \"pmids\": [\"34246804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SMC-specific Tgfb2 conditional knockout in mice causes rapidly progressive thoracic aortic aneurysms with dissection and rupture. Loss of SMC-derived TGFβ2 suppresses canonical SMAD2/3 phosphorylation, activates non-canonical MAPK (p38 and ERK1/2) signaling, and causes SMC de-differentiation (reduced Acta2, Myh11) with ECM disorganization (elastic fiber fragmentation, increased collagen/proteoglycans).\",\n      \"method\": \"Tamoxifen-inducible SMC-specific Cre (Myh11CreERT2), ROSA lineage reporter, histological/morphometric analyses, western blotting for SMAD2/3, p38, ERK1/2, gene expression profiling\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional cell-type-specific KO with molecular signaling readouts, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.10.01.679917\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TGF-β2 secreted by glioma cells decreases TNF-induced VCAM-1 expression on glioma cells and brain-derived endothelial cells; glioma supernatant alone reproduced this effect on CNS endothelial cells in co-culture.\",\n      \"method\": \"Co-culture of A-172 glioma cells with CNS endothelial cells, VCAM-1 expression assay, glioma supernatant experiments\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single method type (expression assay in co-culture), no molecular mechanism of VCAM-1 suppression established\",\n      \"pmids\": [\"9058771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FTO demethylates m6A modifications on TGFB2 mRNA in human BMSCs, increasing TGFB2 expression and promoting osteogenic differentiation; TGFB2 knockdown inhibited osteogenic differentiation downstream of FTO.\",\n      \"method\": \"m6A-seq, FTO knockdown by shRNA, TGFB2 knockdown, osteogenic differentiation assays\",\n      \"journal\": \"Oral diseases\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — m6A-seq identifies modification site, but mechanistic link between FTO demethylation and TGFB2 function relies on KD phenotype alone, single lab\",\n      \"pmids\": [\"40127138\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TIPE activates the P38 MAPK signaling pathway in colorectal cancer cells, leading to increased TGFB2 expression and secretion, which then acts on extracellular macrophages to induce M2 polarization, creating a feedback loop enhancing CRC malignant behavior.\",\n      \"method\": \"TIPE overexpression/knockdown, western blot for P38 MAPK, TGFB2 ELISA, macrophage polarization assays, animal experiments\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — signaling pathway placement via overexpression/knockdown, single lab, no direct biochemical reconstitution of TIPE-P38-TGFB2 axis\",\n      \"pmids\": [\"40391468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RUNX1 promotes cervical cancer cell proliferation by upregulating TGFB2 expression, which activates the MAPK pathway; TGFB2 inhibition impaired MAPK pathway activation and reversed the proliferative effects of RUNX1 overexpression.\",\n      \"method\": \"RUNX1 overexpression/knockdown, TGFB2 inhibition, MAPK pathway western blot, cell cycle and proliferation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement by rescue experiment, single lab, mechanism of RUNX1 regulation of TGFB2 transcription not directly demonstrated\",\n      \"pmids\": [\"39747496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TGFB2 knockdown in H9c2 cells subjected to oxygen-glucose deprivation promoted viability and inhibited apoptosis, reducing cleaved Caspase-3/Caspase-3 and Bax protein levels while increasing Bcl-2, implicating TGFB2 in cardiomyocyte apoptosis signaling in ischemia.\",\n      \"method\": \"TGFB2 knockdown, CCK-8 assay, flow cytometry for apoptosis, western blot for caspase-3, Bax, Bcl-2\",\n      \"journal\": \"Cardiovascular toxicology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method type (KD in cell line) with apoptosis readout, no upstream pathway placement, single lab\",\n      \"pmids\": [\"40080329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TCF12 directly binds the TGFB2 promoter and activates TGFB2 transcription (established by ChIP and dual-luciferase reporter assay), promoting melanoma cell proliferation and metastasis downstream.\",\n      \"method\": \"RNA-seq, qPCR, immunoblotting, ChIP, dual-luciferase reporter assay, subcutaneous tumor formation assay\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — ChIP and luciferase confirm direct promoter binding, but downstream signaling mechanism not fully elucidated; single lab\",\n      \"pmids\": [\"37760480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"STAT2 and SMAD3 are upstream transcription factors for TGFB2 in chicken granulosa cells: DNA pull-down and mass spectrometry identified STAT2 binding to the TGFB2 promoter, and SCENIC single-cell network analysis confirmed this regulatory interaction; the JAK/STAT-TGFB2-SMAD3 axis mediates granulosa cell degeneration during follicular atresia.\",\n      \"method\": \"DNA pull-down assay, mass spectrometry, SCENIC analysis of single-cell RNA sequencing data, ChIP validation\",\n      \"journal\": \"Poultry science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — DNA pull-down in chicken cells identifies binding but functional consequence inferred rather than directly tested; ortholog work in avian, single lab\",\n      \"pmids\": [\"40902342\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TGFB2 encodes a secreted TGF-β ligand that signals canonically through TGFBR1/TGFBR2 (and distinctively through TGFBR3 in aortic root smooth muscle cells) to activate SMAD2/3 phosphorylation, promoting SMC differentiation, ECM homeostasis, EMT, and cell proliferation arrest; haploinsufficiency paradoxically upregulates compensatory TGF-β signaling in aortic tissue causing aneurysm, while gain-of-LAP mutations increase ligand activation causing Camurati-Engelmann disease; TGFB2 expression is regulated at multiple levels including by transcription factors (ΔNp63α, NFATc1, HOXA10, RUNX1, TCF12), epigenetic mechanisms (NF-κB/BRD4-dependent enhancer activation in SSc, histone H3K18 lactylation, FTO-mediated m6A demethylation), and non-coding RNAs, with downstream signaling through SMAD pathways as well as non-canonical RHOA and MAPK cascades.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TGFB2 encodes a secreted TGF-\\u03b2 ligand that signals through TGF-\\u03b2 receptors to activate SMAD2/3 phosphorylation, controlling smooth-muscle-cell differentiation, extracellular-matrix homeostasis, epithelial-to-mesenchymal transition, and cell-proliferation arrest [#15, #12]. In the aorta, TGFB2 haploinsufficiency causes thoracic aortic root aneurysm, and affected tissue paradoxically shows increased canonical and non-canonical TGF-\\u03b2 signaling and elevated TGF-\\u03b22 protein, consistent with an initial drop in cellular ligand triggering a secondary compensatory upregulation [#0, #1]. SMC-specific loss of TGFB2 reproduces this phenotype: it suppresses SMAD2/3 phosphorylation, activates non-canonical p38 and ERK1/2 MAPK signaling, drives SMC de-differentiation, and disorganizes the ECM [#15]. TGFB2 acts in a distinctly isoform-specific manner during SMC differentiation, requiring TGFBR3 (betaglycan) as receptor, such that exogenous TGFB2 cannot rescue differentiation in the absence of TGFBR3 [#8]. Conversely, gain-of-function mutations in the latency-associated peptide straitjacket subdomain of pro-TGF-\\u03b22 reduce ligand inactivation and increase TGF-\\u03b22/SMAD signaling, causing Camurati-Engelmann disease type II with enhanced ossification [#7]. Beyond development and vascular biology, TGFB2 mediates oocyte-driven cumulus expansion via TGFBR1/TGFBR2-SMAD2/3 [#12], enforces a profibrotic state in systemic-sclerosis fibroblasts through autocrine signaling [#3], and can act through non-canonical RHOA to arrest proliferation in squamous carcinoma [#2]. TGFB2 expression is tightly controlled by transcription factors (\\u0394Np63\\u03b1 repression, HOXA10, NFATc1) and by epigenetic and RNA-level mechanisms including enhancer activation, m6A modification, and histone H3K18 lactylation [#2, #5, #3, #6, #9].\",\n  \"teleology\": [\n    {\n      \"year\": 2012,\n      \"claim\": \"Established that TGFB2 dosage is critical for aortic integrity and revealed the counterintuitive principle that loss-of-function ligand mutations elevate tissue TGF-\\u03b2 signaling.\",\n      \"evidence\": \"Tgfb2+/- mouse models plus human linkage/exome sequencing with aortic tissue immunostaining and signaling western blots\",\n      \"pmids\": [\"22772368\", \"22772371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of the compensatory upregulation not defined\", \"Cell type driving the paradoxical signaling increase not resolved at this stage\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed TGFB2 downstream of a transcriptional repressor and defined a non-canonical effector branch, showing TGFB2 induction activates RHOA to enforce proliferation arrest.\",\n      \"evidence\": \"CRISPR screen, \\u0394Np63\\u03b1 knockdown, ectopic TGFB2 expression, neutralizing antibody, and RHOA activity assays in squamous carcinoma cells\",\n      \"pmids\": [\"30232004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating RHOA activation not identified\", \"Generalizability beyond SCC unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrated cis-regulatory control of TGFB2 expression by enhancer elements, linking a GWAS variant and an epigenetically maintained enhancer to autocrine profibrotic signaling.\",\n      \"evidence\": \"3C/chromatin conformation capture, CRISPR/Cas9 enhancer deletion in lung fibroblasts, ATAC-seq, CRISPRi, and NF-\\u03baB/BRD4 inhibition in patient skin explants\",\n      \"pmids\": [\"31343404\", \"31217334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans factors binding the enhancer only partially defined\", \"Whether enhancer regulation operates in vascular tissue not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showed TGFB2 has isoform-specific developmental functions, with RUNX1-dependent TGFB2 (not TGFB1) signaling driving motility and EMT during mesendodermal differentiation.\",\n      \"evidence\": \"RUNX1 siRNA depletion in hESCs with isoform-specific rescue by exogenous TGFB2 versus TGFB1\",\n      \"pmids\": [\"27720906\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of isoform specificity at the receptor level not addressed\", \"Direct RUNX1 binding to TGFB2 locus not shown here\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a physiological paracrine role for oocyte-secreted TGFB2 acting through canonical receptors to drive cumulus expansion.\",\n      \"evidence\": \"Oocytectomized complex culture with exogenous TGFB2, SD208 inhibitor, and Tgfbr2 conditional knockout in granulosa cells\",\n      \"pmids\": [\"36128893\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution versus other oocyte factors not quantified\", \"SMAD-target genes for expansion not fully enumerated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected LAP structural integrity to ligand bioavailability, showing straitjacket-subdomain mutations reduce latency and increase signaling to cause Camurati-Engelmann disease type II.\",\n      \"evidence\": \"Exome sequencing, structural simulations of mutant LAPs, SMAD signaling assay, and osteogenic differentiation of CED2 patient iPS cells\",\n      \"pmids\": [\"39014191\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo skeletal phenotype not modeled genetically\", \"Quantitative activation kinetics of mutant LAP not measured\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved the receptor identity for TGFB2 in SMC differentiation, establishing TGFBR3 dependence that distinguishes TGFB2 from other isoforms.\",\n      \"evidence\": \"hiPSC-derived SMC differentiation, CRISPR/Cas9 and siRNA, 3D tissue rings, and TGFBR3KO epistasis blocking exogenous-TGFB2 rescue\",\n      \"pmids\": [\"40139558\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How TGFBR3 couples TGFB2 to canonical SMAD output not detailed\", \"Relevance to the aneurysm paradox not directly tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Provided cell-autonomous genetic confirmation that SMC-derived TGFB2 maintains aortic SMC identity and ECM, with loss shifting signaling toward non-canonical MAPK.\",\n      \"evidence\": \"SMC-specific tamoxifen-inducible Tgfb2 knockout mice with histomorphometry and SMAD2/3, p38, ERK1/2 western blots (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.10.01.679917\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Causal ordering of SMAD loss versus MAPK gain not dissected\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended TGFB2 transcriptional regulation to metabolic-epigenetic inputs, linking H3K18 lactylation at the promoter to pathological cardiac hypertrophy.\",\n      \"evidence\": \"CUT&TAG, ChIP-qPCR, nascent RNA-seq, AAV-shRNA knockdown/overexpression, and PI3K/AKT inhibition in a transverse aortic constriction mouse model\",\n      \"pmids\": [\"41376590\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Definitive transferase responsible for promoter lactylation not isolated\", \"Reconciliation with protective vascular roles of TGFB2 unaddressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single ligand integrates receptor choice (TGFBR1/2 versus TGFBR3), canonical SMAD versus non-canonical RHOA/MAPK branches, and tissue-specific dosage sensitivity to yield context-dependent outcomes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking the aortic loss-of-function paradox to the CED2 gain-of-function mechanism\", \"Determinants of canonical versus non-canonical branch selection unknown\", \"Structural basis of TGFBR3-dependent isoform specificity uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [8, 12, 7]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [15, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [5, 12, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 12, 2]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 7]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TGFBR1\", \"TGFBR2\", \"TGFBR3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}